Lexeo Therapeutics, Inc. (LXEO) stock
LXEONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$2.85−0.38 (-11.61%)
Close on Nov 17, 2026Market cap $234.24MP/E –Yield –
Lexeo Therapeutics total assets
Total assets on the balance sheet at the end of each period.
Lexeo Therapeutics's total assets was $254.90M at Jun 30, 2026. For fiscal 2025 it was $268.69M, up 82.9% from the year before.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $268.69M | +82.9% |
| FY2024 | Dec 31, 2024 | $146.94M | +5.1% |
| FY2023 | Dec 31, 2023 | $139.81M | +44.0% |
| FY2022 | Dec 31, 2022 | $97.08M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $254.90M | +44.8% |
| Q1 FY2026 | Mar 31, 2026 | $250.36M | +99.2% |
| Q4 FY2025 | Dec 31, 2025 | $268.69M | +82.9% |
| Q3 FY2025 | Sep 30, 2025 | $143.84M | -17.3% |
| Q2 FY2025 | Jun 30, 2025 | $176.07M | -8.3% |
| Q1 FY2025 | Mar 31, 2025 | $125.69M | -41.0% |
| Q4 FY2024 | Dec 31, 2024 | $146.94M | +5.1% |
| Q3 FY2024 | Sep 30, 2024 | $173.87M | +217.7% |
| Q2 FY2024 | Jun 30, 2024 | $192.01M | +97.8% |
| Q1 FY2024 | Mar 31, 2024 | $213.21M | – |
| Q4 FY2023 | Dec 31, 2023 | $139.81M | – |
| Q3 FY2023 | Sep 30, 2023 | $54.72M | – |
| Q4 FY2022 | Dec 31, 2022 | $97.08M | – |
See a number that looks wrong?